📰 7 sources covering this story

Moderna shares surge after it says experimental mRNA cancer treatment passed key test

First covered 2 days ago · latest take 47 mins ago. Compare how each outlet is covering it — and rate the sources you trust.

PBS NewsHour47 mins ago

Moderna and Merck are developing a treatment using an mRNA-based cancer vaccine called intismeran that is designed to be tailored to individual patients based on unique mutations within their tumors.

Trust?Read on PBS NewsHour ↗

Global News19 hrs ago

Moderna’s experimental mRNA cancer treatment progresses, shares spike

Moderna and Merck are developing a treatment using an mRNA-based cancer vaccine designed to be tailored to individual patients based on unique mutations within their tumors.

Trust?Read on Global News ↗

AP News23 hrs ago

Moderna shares surge after it says its experimental mRNA cancer treatment passed a key test

Moderna shares surge after it says its experimental mRNA cancer treatment passed a key test AP News

Trust?Read on AP News ↗

CTV News23 hrs ago

Moderna shares surge after it says its experimental mRNA cancer treatment passed a key test

Moderna shares more than doubled after it announced initial results from a study of an experimental cancer treatment that would be the first of its kind.

Trust?Read on CTV News ↗

Philadelphia Inquirer23 hrs ago

Moderna shares surge after it says its experimental mRNA cancer treatment passed a key test

Moderna shares more than doubled after announcing initial results from a study of an experimental cancer treatment

Trust?Read on Philadelphia Inquirer ↗

The Independent23 hrs ago

Moderna shares surge after it says its experimental mRNA cancer treatment passed a key test

Moderna shares more than doubled after announcing initial results from a study of an experimental cancer treatment

Trust?Read on The Independent ↗

This is Money🏁 first to report2 days ago

AstraZeneca hit by lung cancer drug setback: Pharma giant halts trials of experimental Volrustomig treatment

Astra said its Volrustomig treatment, when combined with chemotherapy, was unlikely to help lung cancer patients live longer than rival offerings.

Trust?Read on This is Money ↗